A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: The use of scanning electron microscopy

Toxicology Mechanisms and Methods

Volumn 23, Issue 5, 2013, Pages 352-359

  Pretorius, Etheresia ^a   Vermeulen, Natasha ^a   Bester, Janette ^a   Lipinski, Boguslaw ^b   Kell, Douglas B ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Ferric iron; Iron chelation; Platelet rich plasma; Purified fibrinogen; Scanning electron microscopy

Indexed keywords

CLIOQUINOL; CURCUMIN; DEFERIPRONE; DEFEROXAMINE MESYLATE; EPIGALLOCATECHIN GALLATE; FERRIC ION; FIBRIN; FIBRINOGEN; IRON; REACTIVE OXYGEN METABOLITE; THROMBIN;

ADULT; ARTICLE; CONTROLLED STUDY; FIBRIN FORMATION; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE; THROMBOCYTE RICH PLASMA;

ADULT; FIBRIN; FIBRINOLYSIS; HUMANS; IRON; IRON CHELATING AGENTS; MICROSCOPY, ELECTRON, SCANNING; YOUNG ADULT;

EID: 84877038303     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.762082     Document Type: Article

References (76)

1. Aderibigbe OR, Pisa PT, Mamabolo RL, et al. (2011). The relationship between indices of iron status and selected anthropometric cardiovascular disease risk markers in an African population: the THUSA study. Cardiovasc J Afr 22:249-56.
2. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. (2007). Curcumin: the Indian solid gold. Adv Exp Med Biol 595:1-75.
3. Ahluwalia N, Genoux A, Ferrieres J, et al. (2010). Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr 140:812-16.
4. Altamura S, Muckenthaler MU. (2009). Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 16:879-95.
5. Anderson LJ, Westwood MA, Holden S, et al. (2004). Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127:348-55. (Pubitemid 39468951)
6. Aruoma OI, Bomford A, Polson RJ, Halliwell B. (1988). Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy. Blood 72:1416-19. (Pubitemid 18265915)
7. Baccan MM, Chiarelli-Neto O, Pereira RM, Esposito BP. (2012). Quercetin as a shuttle for labile iron. J Inorg Biochem 107:34-9.
8. Bae YJ, Yeon JY, Sung CJ, et al. (2009). Dietary intake and serum levels of iron in relation to oxidative stress in breast cancer patients. J Clin Biochem Nutr 45:355-60.
9. Balan V, Baldus W, Fairbanks V, et al. (1994). Screening for hemochromatosis: a cost-effectiveness study based on 12, 258 patients. Gastroenterology 107:453-9. (Pubitemid 24233320)
10. Bareggi SR, Cornelli U. (2012). Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther 18:41-6.
11. Brissot P, Ropert M, Le Lan C, Loreal O. (2012). Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 1820:403-10.
12. Bush AI. (2002). Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23:1031-8. (Pubitemid 35447784)
13. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. (2005). LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 18:277-87. (Pubitemid 40298370)
14. Cooper GJ. (2011). Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 71:1281-320.
15. Du XX, Xu HM, Jiang H, et al. (2012). Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease. Neurosci Bull 28:253-8.
16. Duguid JB. (1946). Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 58:207-12.
17. Esposito BP, Breuer W, Sirankapracha P, et al. (2003). Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102:2670-7. (Pubitemid 37193611)
18. Farmaki K, Tzoumari I, Pappa C, et al. (2010). Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148:466-75.
19. Fenton HJH. (1894). Oxidation of tartaric acid in presence of iron. J Chem Soc 64:899-910.
20. Fiorani M, de Sanctis R, de Bellis R, Dacha M. (2002). Intracellular flavonoids as electron donors for extracellular ferricyanide reduction in human erythrocytes. Free Radic Biol Med 32:64-72. (Pubitemid 34045138)
21. Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ. (2012). Iron mobilization using chelation and phlebotomy. J Trace Elem Med Biol 26:127-30.
22. Gackowski D, Kruszewsk M, Banaszkiewicz Z, et al. (2002). Lymphocyte labile iron pool, plasma iron, transferrin saturation and ferritin levels in colon cancer patients. Acta Biochim Pol 49:269-72. (Pubitemid 135688029)
23. Gackowski D, Kruszewski M, Jawien A, et al. (2001). Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med 31:542-7. (Pubitemid 32728441)
24. Galaris D, Pantopoulos K. (2008). Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit Rev Clin Lab Sci 45:1-23. (Pubitemid 351299652)
25. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. (2005). Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106:3242-50. (Pubitemid 41565925)
26. Grootveld M, Bell JD, Halliwell B, et al. (1989). Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochroma-tosis: characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 264:4417-22. (Pubitemid 19081342)
27. Halliwell B, Gutteridge JM. (1990). Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186:1-85. (Pubitemid 20279941)
28. Haust MD, Wyllie JC, More RH. (1964). Atherogenesis and plasma constituents. I: demonstration of fibrin in the white plaque by the fluorescent antibody technique. Am J Pathol 44:255-67.
29. Hodkova A, Cerna P, Kotyzova D, Eybl V. (2010). The effect of iron(III) on the activity of selenoenzymes and oxidative damage in the liver of rats. Interaction with natural antioxidants and deferiprone. Hemoglobin 34:278-83.
30. Jomova K, Valko M. (2011a). Advances in metal-induced oxidative stress and human disease. Toxicology 283:65-87.
31. Jomova K, Valko M. (2011b). Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des 17:3460-73.
32. Jomova K, Valko M. (2012). Redox cycling mechanisms in the colon. Med Hypotheses 79:418-19.
33. Jomova K, Vondrakova D, Lawson M, Valko M. (2010). Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345:91-104.
34. Kell DB. (2009). Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2:2 doi: 10.1186/1755-8794-2-2.
35. Kell DB. (2010). Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84:825-89.
36. Kim EY, Ham SK, Shigenaga MK, Han O. (2008). Bioactive dietary polyphenolic compounds reduce nonheme iron transport across human intestinal cell monolayers. J Nutr 138:1647-51.
37. Kovacevic Z, Kalinowski DS, Lovejoy DB, et al. (2011). The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem 11:483-99.
38. Kruszewski M. (2003). Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531:81-92. (Pubitemid 37456724)
39. Kruszewski M. (2004). The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 51:471-80. (Pubitemid 38969308)
40. Kwiatkowski JL. (2011). Management of transfusional iron overload-differential properties and efficacy of iron chelating agents. J Blood Med 2:135-49.
41. Lipinski B, Nowak A, Gurewich V. (1974). The organ distribution of 125I-fibrin in the generalized Shwartzman reaction and its relation to leucocytes. Br J Haematol 28:221-31.
42. Lipinski B, Pretorius E. (2012). Novel pathway of ironinduced blood coagulation: implications for diabetes mellitus and its complications. Pol Arch Med Wewn 122:115-22.
43. Ma Y, De Groot H, Liu Z, et al. (2006). Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. Biochem J 395:49-55.
44. Ma Y, Zhou T, Kong X, Hider RC. (2012). Chelating agents for the treatment of systemic iron overload. Curr Med Chem 19:2816-27.
45. Mak JC. (2012). Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol 39:265-73.
46. Marx G, Chevion M. (1985). Fibrinogen coagulation without thrombin: reaction with vitamin C and copper(II). Thromb Res 40:11-18. (Pubitemid 16204022)
47. Millerot-Serrurot E, Bertrand N, Mossiat C, et al. (2008). Temporal changes in free iron levels after brain ischemia Relevance to the timing of iron chelation therapy in stroke. Neurochem Int 52:1442-8.
48. More RM, Movat HZ, Haust DM. (1957). Role of mural fibrin thrombi of the aorta in genesis of arteriosclerotic plaques; report of two cases. Arch Pathol 63:612-20.
49. Perron NR, Brumaghim JL. (2009). A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys 53:75-100.
50. Petrat F, de Groot H, Sustmann R, Rauen U. (2002). The chelatable iron pool in living cells: a methodically defined quantity. Biol Chem 383:489-502. (Pubitemid 34506286)
51. Piga A, Longo F, Duca L, et al. (2009). High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 84:29-33.
52. Pootrakul P, Breuer W, Sametband M, et al. (2004). Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 104:1504-10. (Pubitemid 39166531)
53. Porter JB, Rafique R, Srichairatanakool S, et al. (2005). Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Ann NY Acad Sci 1054:155-68. (Pubitemid 43031020)
54. Robello E, Galatro A, Puntarulo S. (2009). Labile iron pool and ferritin content in developing rat brain gamma-irradiated in utero. Neurotoxicology 30:430-5.
55. Shah SV, Rajapurkar MM. (2009). The role of labile iron in kidney disease and treatment with chelation. Hemoglobin 33:37-85.
56. Shah SV, Rajapurkar MM, Houser, M. (2008). The role of labile iron in acute kidney injury. US Nephrology 3:52-5.
57. Shainoff JR, Page IH. (1972). Deposition of modified fibrinogen within the aortic intima. Atherosclerosis 16:287-305.
58. Small BG, Mccoll BW, Allmendinger R, et al. (2011). Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol 7:902-8.
59. Smith EB. (1994). Lipids and plasma fibrinogen: early and late composition of the atherosclerotic plaque. Cardiologia 39:169-72.
60. Smith EB, Alexander KM, Massie IB. (1976). Insoluble "fibrin" in human aortic intima: quantitative studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density lipoprotein. Atherosclerosis 23:19-39.
61. Srichairatanakool S, Ounjaijean S, Thephinlap C, et al. (2006). Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin 30:311-27. (Pubitemid 43977333)
62. Stadler N, Lindner RA, Davies MJ. (2004). Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24:949-54. (Pubitemid 38620877)
63. Taher A, Musallam KM, El Rassi F, et al. (2009). Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 146:569-72.
64. Tanaka K, Miyake Y, Fukushima W, et al. (2011). Intake of Japanese and Chinese teas reduces risk of Parkinson's disease. Parkinsonism Relat Disord 17:446-50.
65. Tijburg LB, Mattern T, Folts JD, et al. (1997). Tea flavonoids and cardiovascular disease: a review. Crit Rev Food Sci Nutr 37:771-85. (Pubitemid 127348901)
66. Uchida T, Akitsuki T, Kimura H, et al. (1983). Relationship among plasma iron, plasma iron turnover, and reticuloendothelial iron release. Blood 61:799-802. (Pubitemid 13115385)
67. Vlachodimitropoulou E, Sharp PA, Naftalin RJ. (2011). Quercetin-iron chelates are transported via glucose transporters. Free Radic Biol Med 50:934-44.
68. Wang T, Qin L, Liu B, et al. (2004). Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem 88:939-47. (Pubitemid 38199315)
69. Wardman P, Candeias LP. (1996). Fenton chemistry: an introduction. Radiat Res 145:523-31. (Pubitemid 26127159)
70. Weinreb O, Amit T, Mandel S, Youdim MB. (2009a). Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 4:283-96.
71. Weinreb O, Mandel S, Bar-Am O, et al. (2009b). Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 6:163-74.
72. Whitnall M, Richardson DR. (2006). Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 13:186-97. (Pubitemid 44709656)
73. Woolf N. (1961). The distribution of fibrin within the aortic intima: an immunohistochemical study. Am J Pathol 39:521-32.
74. Yu Y, Gutierrez E, Kovacevic Z, et al. (2012). Iron chelators for the treatment of cancer. Curr Med Chem 19:2689-702.
75. Zacharski LR, Chow BK, Howes PS, et al. (2008). Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 100:996-1002. (Pubitemid 352019800)
76. Zacharski LR, Shamayeva G, Chow BK. (2011). Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 162:949-57.